Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: KEGG:D01817 (Iohexol)
504 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have compared the usefulness of a newly developed, low osmolality contrast medium, Omnipaque 350 (75.49% iohexol, 350 mgI ml-1), for sialography with one of the established, Angioconray (80% sodium iothalamate, 480 mgI ml-1), in a double-blind, prospective randomized clinical trial in 80 patients. The diagnostic quality of the sialograms, pain during the procedure and discomfort subsequently were investigated. There was no difference in either group between the number of sialograms judged as diagnostically useful, although those of excellent quality were significantly more frequent in the Angioconray group. The level of pain on injection of the medium was significantly lower in the Omnipaque group. Eighteen per cent of the patients with Omnipaque had severe or moderate pain on injection of the contrast medium, while 63% had such pain with Angioconray. There was no difference in postprocedural discomfort between the two contrast media. We concluded that the low osmolality contrast medium is more favourable for sialography despite its lower iodine content.
...
PMID:Radiographic quality and patient discomfort in sialography: comparison of iohexol with iothalamate. 193 22

The effects of four different radiographic contrast media (Urovison 58%, Hexabrix 320, Iopamiro 370 and Omnipaque 300) have been examined with respect to histamine release, cardiovascular changes and adverse drug reaction (ADR) in a group of 200 patients undergoing intravenous urography. Each patient received only one of the four agents, which were allocated on a random basis. Urovison produced the greatest number of ADRs. Iopamiro caused the least. No significant correlation between the magnitude of the change in plasma histamine following injection of radiographic contrast medium and the production of a particular ADR could be demonstrated. Heart rate increased significantly following the administration of Urovison, Hexabrix and Iopamiro in the absence of any appreciable change in blood pressure. These results and our earlier findings would favour the use of the low-osmolality contrast media in intravenous urography to minimize ADRs, histamine release and patient discomfort.
...
PMID:Adverse reactions during intravenous urography: are these due to histamine release? 245 Jun 12

Dacryocystography has been widely used in the assessment of the nasolacrimal duct system, particularly in patients with epiphora. Our study was undertaken to evaluate image quality and level of patient discomfort during examinations with water-soluble contrast agents (iohexol [Omnipaque 240], iopamidol [Isovue 200 and 300], and 52.7% diatrizoate meglumine and 26.9% iodipamide meglumine [Sinografin]) compared with the iodized oil-based contrast agent Lipiodol. Fifty-five dacryocystograms were obtained from 41 consecutive patients. The procedure was performed first with a water-soluble contrast agent, then repeated with Lipiodol. A distention technique was used with conventional radiography. Patients were asked to evaluate their level of discomfort (none, mild, moderate, severe). The images were evaluated separately by two radiologists, blinded to which water-soluble agent was employed, and the images were graded on a five-point scale. Images obtained with Lipiodol were significantly better than those with other agents (P less than .02), and image quality deteriorated as iodine concentration decreased. Use of Isovue 300 and Sinografin produced significantly more patient discomfort (P less than .03) than the use of other agents. The authors conclude that, in most instances, Lipiodol is the contrast agent of choice with regard to both highest level of patient comfort and greatest conventional radiographic image quality among the agents compared.
...
PMID:Dacryocystography: comparison of water-soluble and oil-based contrast agents. 255 62

The comparative adequacy was investigated of a nonionic contrast medium (iohexol) versus the ionic contrast medium usually employed in hysterosalpingography. The contrast radiologic features and the radiodiagnostic possibilities of both cm are definitely good. The nonionic contrast medium diffuses quickly and causes the uterine cavity to expand less than ionic contrast media do, thus allowing a better depiction of mucosal and/or parietal pathology. Moreover, nonionic cm allows tubal patency and peritoneal diffusion to be clearly demonstrated, particularly in uncertain cases. As compared to ionic cm, Iohexol did not cause any side effects, except for a mild discomfort. Our results lead us to suggest the use of nonionic contrast medium as the routine contrast medium in hysterosalpingography.
...
PMID:[Use of a nonionic contrast medium (Omnipaque 350) in hysterosalpingography. A comparison with ionic contrast media]. 272 42

Decreasing or alleviating pain experienced by some patients during or after temporomandibular arthrography would make this relatively inexpensive and highly accurate technique more attractive. This is particularly true for those patients without access to MR or those whose referring physicians prefer arthrography to other techniques for diagnosing internal derangements. Ionic and nonionic contrast agents were compared in a randomized, double-blind trial to determine if pain could be decreased by using a nonionic contrast material. Forty patients received either Omnipaque 300 (nonionic, iohexol) or Hypaque 60 (ionic, diatrizoate meglumine). Radiographs were assessed for diagnostic quality, and patients were asked to note their level of discomfort. No significant differences between the agents were detected. Maximal discomfort was noted at 24 hr. Discomfort was classified as none, mild, or moderate, with no patients describing marked discomfort. This study does not support the use of nonionic contrast agents over the less expensive ionic agents for decreasing pain or improving film quality in temporomandibular joint arthrography.
...
PMID:Comparison of omnipaque with hypaque in temporomandibular arthrography. 281 36

A double-blind, cross-over trial of the non-ionic, low-osmolar contrast medium iohexol (Omnipaque) and the ionic, low-osmolar medium ioxaglate (Hexabrix) at concentrations of 300 mg I/ml was carried out in 107 consecutive patients with arterial insufficiency of the lower limbs. The purpose of the study was to observe possible 'carry-over' effects from any of the contrast media, and to evaluate patient discomfort such as pain, adverse reactions, or effect on peripheral blood pressure. No carry-over effect was seen. Ioxaglate caused less injection pain and heat sensations than iohexol, and showed less effect on the systemic blood pressure.
...
PMID:Iohexol and ioxaglate in peripheral angiography. 296 17

Relative patient discomfort resulting from carotid injections of three new low-osmolality contrast agents was assessed in 78 patients. Omnipaque-300 (iohexol), Isovue-300 (iopamidol), and hexabrix (ioxaglate) were sequentially injected into both common carotid arteries of each patient. Patients were asked to rank the relative intensities of the three injections on each side. Mean patient rankings revealed that Hexabrix was preferred most often, Omnipaque-300 next, and Isovue-300 the least. The differences are statistically significant. We conclude that while patients usually tolerated all intracarotid low-osmolality contrast agents rather well, the agent preferred most often was Hexabrix.
...
PMID:Three new low-osmolality contrast agents: a comparative study of patient discomfort. 312 66

The arthrographic image quality and relative morbidity resulting from use of Omnipaque 300 (iohexol), Hexabrix 320 (ioxaglate sodium meglumine), and Isopaque Coronar 370 (metrizoate) were compared in a prospective double-blind study performed with 120 patients. Radiographs obtained 2, 5, 10, 15, 20, and 25 minutes after injection were judged for diagnostic quality. Relative morbidity was evaluated by the physician during the examination and later by the patient via a questionnaire. Hexabrix demonstrated the best and most persistent diagnostic quality over serial radiographs (P less than .05). Omnipaque caused significantly less postprocedural pain (P less than .05). The other types of discomfort measured did not indicate statistically significant differences in morbidity resulting from the three contrast agents.
...
PMID:Knee arthrography: a comparison of iohexol, ioxaglate sodium meglumine, and metrizoate. 354 35

The chemistry of low-osmolality contrast agents is reviewed, the effects of these agents on vascular and organ physiology are compared with the effects of conventional ionic contrast media, and guidelines for intravascular use of the low-osmolality agents in selected high-risk patients are presented. Three low-osmolality contrast agents, the nonionic media iohexol (Omnipaque, Winthrop-Breon) and iopamidol (Isovue, Squibb) and the dimeric medium ioxaglate meglumine-sodium (Hexabrix, Mallinckrodt) have recently been introduced into the contrast-media market. Compared with conventional ionic contrast media, these new agents demonstrate approximately one third of the osmolality per given iodine concentration (degree of roentgenographic opacification). Therefore, the risks of hyperosmolarity-induced reactions to contrast media are lower with the new agents. The low-osmolality agents may be associated with a reduced incidence of contrast-media-induced hypersensitivity reactions. Because of their lower osmolality, these agents produce less vessel dilation, vascular endothelial damage, and associated pain and discomfort than equi-iodine concentrations of the conventional ionic media. They also demonstrate a reduction in the incidence and severity of contrast-media-induced renal vasoconstriction and proteinuria, hemodynamic alterations, negative chronotropic effects, depression of myocardial contractility, and neurotoxicity in the presence of an altered blood-brain barrier. These low-osmolality agents produce fewer undesirable physiological effects than conventional contrast agents, but the cost of the new products can be more than 10 times as great. Therefore, the new products should be used selectively in patients known to be at increased risk for reactions to intravascular contrast media. A scoring system was developed to permit rapid recognition of documented single or multiple risk factors and subsequent determination of whether to administer a low-osmolality agent.
...
PMID:Evaluation of intravascular low-osmolality contrast agents. 378 Jan 59

Ionic contrast media currently used in cerebral angiography frequently cause discomfort due to hyperosmolality. This double-blind, multicenter trial compared two ionic media, meglumine iothalamate and meglumine-Na diatrizoate, with the new nonionic agent, iohexol, in 277 patients undergoing cerebral angiography. Vital signs, cardiovascular changes, and neurologic status were evaluated before, during, and after injection. Patients were observed for adverse reactions for up to 24 hours following studies. Patient discomfort and image quality were evaluated. Visualization was good or excellent with all media studied. No significant physiological differences were observed between the ionic and iohexol groups, but fewer iohexol patients experienced large increases (greater than 20 mmHg) in systolic blood pressure. Iohexol patients experienced significantly less discomfort; ionic patients reported severe discomfort 21/2 times more often. This finding was attributed to iohexol's low osmolality. Iohexol may be indicated particularly for use in selective angiograms where discomfort is a factor and for patients suspected of having blood-brain barrier disruption.
...
PMID:Iohexol cerebral angiography. Multicenter clinical trial. 388 17


1 2 3 Next >>

---